levodopa has been researched along with nebicapone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hainzl, D; Loureiro, AI; Parada, A; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Parada, A; Soares-da-Silva, P | 1 |
| Parada, A; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Almeida, L; Falcão, A; Loureiro, A; Machado, R; Maia, J; Silveira, P; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Almeida, L; Costa, R; Falcão, A; Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, J; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Almeida, L; Costa, R; Falcão, A; Fernandes-Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, JF; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Bonifácio, MJ; Falcão, A; Lobo, JS; Machado, R; Soares-da-Silva, P; Sousa e Silva, JP | 1 |
| Kiss, LE; Soares-da-Silva, P | 1 |
4 trial(s) available for levodopa and nebicapone
| Article | Year |
|---|---|
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine | 2003 |
Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Topics: Acetophenones; Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Time Factors; Tyrosine; Young Adult | 2008 |
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine; Young Adult | 2009 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
5 other study(ies) available for levodopa and nebicapone
| Article | Year |
|---|---|
BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Methylation; Rats; Rats, Wistar; Time Factors; Tyrosine | 2001 |
BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
Topics: Acetophenones; Animals; Antiparkinson Agents; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Levodopa; Liver; Male; Methylation; Microdialysis; Rats; Rats, Wistar | 2003 |
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Topics: Acetophenones; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Corpus Striatum; Dihydroxyphenylalanine; Drug Interactions; Erythrocytes; Humans; In Vitro Techniques; Levodopa; Liver; Methylation; Methyldopa; Microdialysis; Rats; Rats, Wistar | 2003 |
In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs.
Topics: Acetophenones; Animals; Antiparkinson Agents; Area Under Curve; Carbidopa; Delayed-Action Preparations; Drug Carriers; Levodopa; Swine; Swine, Miniature; Tablets; Technology, Pharmaceutical | 2011 |
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Topics: Acetophenones; Animals; Catalysis; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Levodopa; Male; Models, Molecular; Nitriles; Oxadiazoles; Parkinson Disease; Prodrugs; Rats | 2014 |